COMPANY
Sanofi
FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Regulatory Project Coordinator Supporting Trainee | Budapest | Oct 21, 2026 | Oct 21, 2026 |
| QC Training Coördinator | Geel | Oct 21, 2026 | Oct 21, 2026 |
| 疫苗事业部-Commercial Intern-绍兴 | Shaoxing | Oct 21, 2026 | Oct 21, 2026 |
| 糖尿病事业部 医学信息沟通代表 绵阳 | Mianyang | Oct 21, 2026 | Oct 21, 2026 |
| Scientific Sales Executive | Hyderabad | Oct 21, 2026 | Oct 21, 2026 |
Timeline
- Trial start Phase 1: Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function source ↗
- Trial start Phase 4: Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 source ↗
- Trial start Phase 1: An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition source ↗
- Trial start Phase 3: A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) source ↗
- Trial start Phase 3: Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China source ↗
- Trial start Phase 2: A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease source ↗
- Trial start 1: Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older source ↗
- Trial start Phase 2: A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) source ↗
- Trial start Phase 4: Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica source ↗
- Trial start —: A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice source ↗
- Trial start Phase 3: A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease source ↗
- Trial start Phase 3: Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age source ↗
- Trial start Phase 2: A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa source ↗
- Trial start Phase 2: A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) source ↗
- Trial start —: This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment source ↗
- Trial start Phase 2: A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission source ↗
- Trial start Phase 1/Phase 2: A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration source ↗
- Trial start Phase 3: An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease source ↗
- Trial start Phase 3: A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease source ↗
- Trial start Phase 4: A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. source ↗
- Trial start Phase 3: Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by source ↗
- Trial start Phase 3: Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by a source ↗
- Trial start Phase 2: A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease source ↗
- Trial start Phase 3: A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia source ↗
- Trial start Phase 2: A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis source ↗
Upcoming milestones
- Nov 3, 2026 (ESTIMATED) · Phase 1 · An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition · NCT07855250
- Nov 6, 2026 (ESTIMATED) · · Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan · NCT06052800
- Nov 26, 2026 (ESTIMATED) · Phase 4 · Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 · NCT07861542
- Dec 17, 2026 (ESTIMATED) · Phase 2 · A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis · NCT06975722
- Dec 23, 2026 (ESTIMATED) · Phase 2 · A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease · NCT06500702
- Feb 11, 2027 (ESTIMATED) · Phase 2 · A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease · NCT06984627
- Apr 8, 2027 (ESTIMATED) · Phase 2 · A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission · NCT07156175
- Apr 21, 2027 (ESTIMATED) · Phase 1 · Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function · NCT07853131
Funding
- Partnership / licensing: €50M (upfront, as published), announced Dec 23, 2024. Source: SEC filing. source ↗
Clinical trials (lead sponsor) Showing 50 of 1,209
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06975722 | A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis | Phase 2 | Active, not recruiting | Jul 7, 2025 | Dec 17, 2026 (estimated) |
| NCT04751487 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Feb 12, 2021 | Apr 21, 2025 (actual) |
| NCT07556159 | A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice | Not listed | Recruiting | Apr 1, 2026 | Apr 4, 2029 (estimated) |
| NCT06052800 | Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan | Not listed | Active, not recruiting | Sep 13, 2023 | Nov 6, 2026 (estimated) |
| NCT06280391 | A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis | Phase 2 | Completed | Feb 20, 2024 | Sep 16, 2025 (actual) |
| NCT07861542 | Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 | Phase 4 | Not yet recruiting | Oct 2, 2026 | Nov 26, 2026 (estimated) |
| NCT07348692 | Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | Phase 3 | Recruiting | Jan 20, 2026 | Jun 7, 2027 (estimated) |
| NCT06033833 | Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | Phase 2 | Terminated | Sep 5, 2023 | Sep 22, 2026 (actual) |
| NCT07855250 | An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition | Phase 1 | Recruiting | Oct 1, 2026 | Nov 3, 2026 (estimated) |
| NCT05991323 | Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study | Not listed | Completed | Dec 12, 2023 | Sep 8, 2026 (actual) |
| NCT07853131 | Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function | Phase 1 | Not yet recruiting | Oct 9, 2026 | Apr 21, 2027 (estimated) |
| NCT07190222 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Recruiting | Sep 17, 2025 | Nov 27, 2029 (estimated) |
| NCT06984627 | A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | Phase 2 | Recruiting | Sep 2, 2025 | Feb 11, 2027 (estimated) |
| NCT06101095 | A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) | Phase 4 | Active, not recruiting | Nov 29, 2023 | Nov 5, 2025 (actual) |
| NCT06859099 | Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP | Phase 3 | Enrolling by invitation | Apr 1, 2025 | Oct 3, 2029 (estimated) |
| NCT05757713 | Teplizumab in Pediatric Stage 2 Type 1 Diabetes | Phase 4 | Completed | Jul 25, 2023 | Aug 28, 2026 (actual) |
| NCT05911763 | A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A | Not listed | Active, not recruiting | Jun 30, 2023 | Jun 6, 2028 (estimated) |
| NCT04401020 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Phase 1 | Terminated | Jul 24, 2020 | Mar 2, 2024 (actual) |
| NCT04717375 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Phase 1/Phase 2 | Terminated | Apr 11, 2021 | Jul 2, 2025 (actual) |
| NCT07290803 | This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment | Not listed | Recruiting | Nov 17, 2025 | Jan 30, 2034 (estimated) |
| NCT04879628 | Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis | Phase 2 | Active, not recruiting | Jun 7, 2021 | Sep 21, 2022 (actual) |
| NCT06837454 | French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | Not listed | Active, not recruiting | Feb 4, 2025 | May 13, 2027 (estimated) |
| NCT06684314 | A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan | Not listed | Active, not recruiting | Nov 11, 2024 | Aug 28, 2031 (estimated) |
| NCT06867094 | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis | Phase 2 | Active, not recruiting | Mar 28, 2025 | Aug 6, 2026 (actual) |
| NCT07734649 | Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older | 1 | Recruiting | Jul 22, 2026 | May 3, 2028 (estimated) |
| NCT06039241 | Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis | Not listed | Active, not recruiting | Mar 7, 2023 | Mar 8, 2028 (estimated) |
| NCT06082037 | A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction | Phase 3 | Recruiting | Oct 10, 2023 | Jan 29, 2029 (estimated) |
| NCT07184944 | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Phase 3 | Recruiting | Jan 22, 2026 | Aug 13, 2029 (estimated) |
| NCT07156175 | A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission | Phase 2 | Recruiting | Oct 14, 2025 | Apr 8, 2027 (estimated) |
| NCT06500702 | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease | Phase 2 | Recruiting | Dec 19, 2024 | Dec 23, 2026 (estimated) |
| NCT07184931 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease | Phase 3 | Recruiting | Oct 1, 2025 | May 14, 2029 (estimated) |
| NCT02991469 | A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) | Phase 2 | Recruiting | Aug 9, 2018 | Mar 1, 2028 (estimated) |
| NCT07190196 | A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease | Phase 3 | Recruiting | Sep 26, 2025 | Jun 28, 2028 (estimated) |
| NCT06145373 | A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab | Phase 4 | Recruiting | Mar 1, 2024 | May 28, 2028 (estimated) |
| NCT07053423 | A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. | Phase 4 | Recruiting | Sep 22, 2025 | Dec 23, 2028 (estimated) |
| NCT07116031 | A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) | Phase 2 | Recruiting | Dec 2, 2025 | Sep 25, 2028 (estimated) |
| NCT07710872 | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China | Phase 3 | Recruiting | Aug 22, 2026 | Mar 13, 2028 (estimated) |
| NCT07086976 | A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia | Phase 3 | Recruiting | Aug 18, 2025 | May 31, 2028 (estimated) |
| NCT07222189 | A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) | Phase 2 | Active, not recruiting | May 19, 2026 | Sep 30, 2026 (estimated) |
| NCT07688213 | A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease | Phase 2 | Recruiting | Jul 28, 2026 | Jul 31, 2029 (estimated) |
| NCT05039840 | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Phase 2 | Active, not recruiting | Nov 10, 2021 | Sep 4, 2026 (actual) |
| NCT07215234 | A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 1/Phase 2 | Recruiting | Oct 9, 2025 | Oct 13, 2027 (estimated) |
| NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Recruiting | Sep 16, 2025 | Nov 27, 2029 (estimated) |
| NCT07286214 | Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica | Phase 4 | Recruiting | May 12, 2026 | Jun 4, 2029 (estimated) |
| NCT06676319 | Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Phase 2 | Active, not recruiting | Nov 7, 2024 | Jun 21, 2027 (estimated) |
| NCT07225569 | A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Phase 2 | Recruiting | Dec 29, 2025 | Sep 22, 2027 (estimated) |
| NCT06290141 | A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 3 | Recruiting | Aug 21, 2024 | Jul 9, 2027 (estimated) |
| NCT07094373 | Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data | Not listed | Recruiting | Jan 1, 2025 | Sep 30, 2026 (estimated) |
| NCT06637631 | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | Phase 2 | Active, not recruiting | Dec 10, 2024 | Jul 30, 2026 (actual) |
| NCT07793409 | A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Recruiting | Sep 16, 2026 | Jul 23, 2031 (estimated) |
Open jobs 999
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Regulatory Project Coordinator Supporting Trainee | Budapest | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| QC Training Coördinator | Geel | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| 疫苗事业部-Commercial Intern-绍兴 | Shaoxing | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| 糖尿病事业部 医学信息沟通代表 绵阳 | Mianyang | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Scientific Sales Executive | Hyderabad | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Head of Clean Utilities and Sustainability | City of Singapore | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Head of Trade CZ | Praha | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Employee Life Cycle Excellence Lead Africa | 2 locations (listed on the posting) | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| stage 2 mois assurance qualité opérationnelle | Val-de-Reuil | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| S2P Digital Process Specialist | Hyderabad | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Market Access-Regional Access Policy & Strategy Manager - Shanghai | Shanghai | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| stage 6 mois coordination projets IA | Lyon | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| stage 6 mois coordination innovation | Lyon | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| I&A Intern | Shanghai | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Patient Solutions Coordinator | Mumbai | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| 糖尿病事业部 医学信息沟通代表 成都 | Chengdu | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| CSA Rare Hematology Mastocitosi_Piemonte, Liguria e Valle d’Aosta | Milano | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Pharmaziepraktikant*in im Bereich Medical Affairs - Immuno-Respiratory für Mai 2027 | Berlin | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| stage 6 mois optimisation projets production | Aramon | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| CSA Rare Hematology Mastocitosi_Sicilia e Calabria | Milano | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| stage 6 mois support production | Aramon | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| internship 6 months – public affairs vaccines | Lyon | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| CSA Rare Hematology Mastocitosi_Toscana, Umbria e Marche | Milano | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| CSA Rare Hematology Mastocitosi_Lazio, Abruzzo e Sardegna | Milano | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Senior Scientific Writer | Hyderabad | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Senior Analyst - Customer Facing Effectiveness | Hyderabad | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Accounting Analyst | Hyderabad | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Head of Immunology | Barangaroo | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Medical Science Liaison, Rare Hematology (NYC) | New York City, NY | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| 特药事业部 医学信息沟通代表 广州 | Guangzhou | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Order-to-Serve (O2S) Protege | Kuala Lumpur | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| O2C Cash Application Receivables and Revenue Management Protege (Mandarin Speaker) | Kuala Lumpur | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Position Order to Serve (O2S) Protege | Kuala Lumpur | Oct 21, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders Mid-Atlantic | Virginia | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders Tri-State | Bridgewater, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders South Atlantic | Bridgewater, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders Central West | Bridgewater, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders Great Lakes | Bridgewater, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders Central East | Bridgewater, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Key Account Manager, Rare Blood Disorders Southwest | Bridgewater, NJ | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| 2027 Spring Co-op Neuroscience Research, Cambridge, MA | Cambridge, MA | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Digital Consumer Experience Strategy Lead | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Demand Lead | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Automation Lead | Toronto, ON | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Director, Access Strategy Oncology | 2 locations (listed on the posting) | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Regional Treasury Center Senior Analyst | Bogota | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Customer Engagement Lead Immunology DA | Buenos Aires | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Production Engineer | Cuautitlan Izcalli | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Medical Science Liaison Rhino Gastroenterology West | Cambridge, MA | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| O2C Credit and Collection Protege (Mandarin Speaker) | Petaling Jaya | Oct 20, 2026 | Oct 21, 2026 | Not stated |